Study guide

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events

Key Takeaways Explain This Topic AI

Live vaccines are contraindicated in pregnancy and significant immunosuppression, and two live parenteral vaccines are given the same day or at least 4 weeks apart.

NACI recommends one dose of Pneu-C-20 or Pneu-C-21 at 65 and older, two doses of recombinant zoster vaccine from 50, Tdap in every pregnancy (ideally 27 to 32 weeks), and RSV vaccine for all adults 75 and older.

Infants receive IM vaccines in the anterolateral thigh, and adults in the deltoid, usually with a 1 inch needle and without aspiration.

Vaccines are stored at +2 to +8°C in a purpose-built refrigerator with twice-daily temperature logs; excursions are quarantined until public health or the manufacturer advises.

Egg allergy is not a contraindication to influenza vaccine, patients are observed for 15 minutes, and anaphylaxis is treated with IM epinephrine 0.01 mg/kg (maximum 0.5 mg).

Last updated: October 2026

Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events

Pharmacists in every province now give vaccines. Influenza and COVID-19 vaccines are the most common, but many pharmacists also give a growing list of routine adult, travel and catch-up vaccines. National advice comes from the National Advisory Committee on Immunization (NACI) and is compiled in the Canadian Immunization Guide (CIG) . Each province decides which vaccines are publicly funded and which ones pharmacists may give.

1. Vaccine Types and Spacing

Live attenuated vaccines: measles-mumps-rubella (MMR), varicella, rotavirus, yellow fever, oral typhoid, BCG, and live attenuated influenza where available.

Contraindicated in pregnancy and in significant immunosuppression (high-dose corticosteroids, chemotherapy, biologics).

Spacing: two live parenteral vaccines are given on the same day or at least 4 weeks apart .

Inactivated, subunit, toxoid, conjugate and mRNA vaccines can be given at any interval from other vaccines, and are generally safe in pregnancy when indicated.

Interrupted series: do not restart. Continue where the schedule left off.

2. Key Adult Recommendations (NACI)

  • Vaccine Who Schedule
  • Influenza Everyone 6 months and older without contraindications Every fall

Td / Tdap All adults: one Tdap dose in adulthood; every pregnancy Td booster every 10 years; in pregnancy Tdap ideally at 27 to 32 weeks (may be given from 13 weeks up to delivery)

Pneumococcal conjugate (Pneu-C-20 or Pneu-C-21) Adults 65 and older , and adults under 65 at increased risk of invasive pneumococcal disease One dose , regardless of earlier Pneu-C-13, Pneu-C-15 or Pneu-P-23 (usually at least 1 year after the last pneumococcal dose)

Recombinant zoster vaccine (RZV, Shingrix) Adults 50 and older ; may also be offered to immunocompromised adults 18 and older 2 doses, 2 to 6 months apart , even after previous shingles or the older live zoster vaccine

RSV (older adults) NACI, April 2026: all adults 75 and older ; adults 65 to 74 at increased risk ; adults 18 and older in long-term care, on home oxygen, on dialysis, or after lung or stem-cell transplant A single dose (protection lasts at least 3 seasons)

HPV NACI's current schedule: 1 dose for ages 9 to 20 , 2 doses for ages 21 to 26, and 3 doses for immunocompromised people or those living with HIV Per age group

Hepatitis B, hepatitis A, MMR, varicella Non-immune adults at risk, health care workers, travellers; MMR for adults born in 1970 or later without documented immunity Per product

3. Administration Technique

Intramuscular (IM) sites and needle length:

Infants under 12 months: the anterolateral thigh (vastus lateralis), usually a 5/8 to 1 inch needle.

Toddlers: the thigh or deltoid, depending on muscle mass.

Children over 3 years and adults: the deltoid , usually a 1 inch (25 mm) needle, longer for larger adults. The 5/8 inch needle is generally for subcutaneous injection or very small deltoids.

Gauge: 22 to 25.

Subcutaneous injections use a 5/8 inch, 25 gauge needle at 45° into the upper outer triceps or the thigh.

No aspiration before IM vaccine injection. It adds pain without benefit.

Several vaccines at one visit: separate sites, at least 2.5 cm apart, and record each site.

Pain reduction: for children, use breastfeeding, sweet solutions or topical anesthetic, distraction, an upright position, and give the most painful vaccine last.

Documentation: product, lot, dose, site, route, date and the immunizer. Update the provincial registry, and give the patient a record.

4. Storage and the Cold Chain

Refrigerated vaccines are kept at +2 to +8°C in a purpose-built (pharmaceutical-grade) refrigerator, not in the door or a bar fridge. Use continuous digital min/max temperature monitoring, checked and logged at least twice daily .

Never freeze vaccines that should be refrigerated. Frozen aluminum-adjuvanted vaccines lose potency.

After a temperature excursion: label the vaccines "Do not use", keep them refrigerated, record the times and temperatures, and contact public health or the manufacturer before using or discarding them.

5. Contraindications, Precautions and Adverse Events

True contraindication: anaphylaxis to a previous dose or to a vaccine component.

Precautions: moderate or severe acute illness (defer), and Guillain-Barré syndrome within 6 weeks of a previous influenza vaccine.

Not reasons to delay: mild illness or low-grade fever, antibiotic use, or a family history of reactions.

Egg allergy is not a contraindication to influenza vaccine, even with a history of anaphylaxis to eggs. The vaccine can be given in any usual setting with standard observation.

Observation: observe for 15 minutes after vaccination (30 minutes if there is a specific concern). Seat adolescents, who are prone to fainting.

Anaphylaxis: give epinephrine 1 mg/mL IM, 0.01 mg/kg (maximum 0.5 mg) in the anterolateral thigh, call 911, and repeat every 5 to 15 minutes if needed (section 2.2).

Report adverse events following immunization (AEFI) to the local public health unit. Provinces forward these reports to PHAC's national surveillance system.

  • 6. Addressing Vaccine Hesitancy
  • Use a presumptive approach: "You're due for your flu and shingles vaccines today."

Listen and respond with motivational interviewing: acknowledge concerns, ask permission before sharing information, and focus on what matters to the patient.

Correct misinformation without repeating myths at length, and share personal recommendations.

Document refusals and offer the vaccine again at later visits.